CSF and Blood Biomarkers in Progressive Supranuclear Palsy

Cerebrospinal fluid (CSF) and blood-based biomarkers represent minimally invasive approaches for diagnosis, differential diagnosis, and disease monitoring in progressive supranuclear palsy (PSP). These biomarkers reflect the underlying neuropathological processes including tau pathology, neurodegeneration, and neuroinflammation.

Overview of Fluid Biomarkers

flowchart TD
    CSF["CSF"] -->|"involved in"| Glymphatic_Pathway["Glymphatic Pathway"]
    CSF["CSF"] -->|"contains"| PD_ProS["PD_ProS"]
    CSF["CSF"] -->|"activates"| AQP4["AQP4"]
    CSF["CSF"] -->|"inhibits"| MELANOMA["MELANOMA"]
    CSF["CSF"] -->|"regulates"| TAU["TAU"]
    CSF["CSF"] -->|"interacts with"| SYK["SYK"]
    CSF["CSF"] -->|"activates"| SYK["SYK"]
    CSF["CSF"] -->|"interacts with"| ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"]
    CSF["CSF"] -->|"phosphorylates"| NEURODEGENERATION["NEURODEGENERATION"]
    CSF["CSF"] -->|"exacerbates"| NEURODEGENERATION["NEURODEGENERATION"]
    CSF["CSF"] -->|"interacts with"| MICROGLIAL_ACTIVATION["MICROGLIAL ACTIVATION"]
    CSF["CSF"] -->|"biomarker for"| ALZHEIMER["ALZHEIMER"]
    CSF["CSF"] -->|"regulates"| MICROGLIA["MICROGLIA"]
    CSF["CSF"] -->|"phosphorylates"| ALZHEIMER["ALZHEIMER"]
    style CSF fill:#4fc3f7,stroke:#333,color:#000

Fluid biomarkers in PSP can be categorized into several groups:

Cerebrospinal Fluid Biomarkers

Tau Proteins in CSF

Total Tau (t-tau)

Total tau reflects neuronal damage and axonal degeneration:

• Elevated levels in PSP compared to healthy controls^{1CSF tau as a biomarker for progressive supranuclear palsy2019 · PMID 31479623Open reference}

• Correlates with disease severity and progression^{2Neurofilament light chain in CSF and plasma as progression markers in PSP2022 · PMID 34897654Open reference}

• Higher levels in PSP-RS compared to PSP-P variants

• Distinguishes PSP from Parkinson’s disease

Phosphorylated Tau (p-tau)

Phosphorylated tau at specific epitopes provides disease-specific information:

• p-tau181: Elevated in PSP vs. PD, but lower than AD^{3CSF tau phosphorylated at threonine 181 in PSP2023}

• p-tau217: Higher sensitivity for 4R-tauopathies like PSP

• p-tau231: Correlates with disease duration

• The 4R-tau isoforms predominate in PSP, affecting p-tau patterns

Tau Fragments and Tau Oligomers

• Tau fragments: C-terminal fragments elevated in PSP CSF

• Tau oligomers: Emerging biomarker with high specificity

• Correlate with tau aggregate load in brain

Neurodegeneration Markers

Neurofilament Light Chain (NfL)

NfL is a marker of axonal damage:

• Markedly elevated in PSP CSF compared to controls^{4Neurofilament light chain as a biomarker in PSP2020 · PMID 32847921Open reference}

• Higher than in Parkinson’s disease but lower than in ALS

• Correlates with disease progression rate

• Predicts clinical deterioration

• Useful for disease monitoring in clinical trials

Neuron-Specific Enolase (NSE)

• Elevated in PSP CSF^{5Neuron-specific enolase in CSF and plasma in neurodegenerative diseases2018}

• Reflects neuronal loss

• Correlates with cognitive impairment

Ubiquitin C-Terminal Hydrolase L1 (UCH-L1)

• Elevated in PSP CSF

• Associated with neurodegeneration

• May distinguish PSP from other parkinsonian syndromes

Neuroinflammation Markers

Interleukin-6 (IL-6)

• Elevated in PSP CSF^{6Interleukin-6 in CSF and plasma in PSP2020}

• Correlates with disease severity

• Reflects ongoing neuroinflammatory processes

Tumor Necrosis Factor-alpha (TNF-α)

• Increased levels in PSP CSF

• Associated with disease progression

• Therapeutic target potential

YKL-40 (Chitinase-3-Like Protein 1)

• Elevated in PSP CSF^{7YKL-40 as biomarker in PSP and related disorders2021}

• Marker of microglial activation

• Correlates with disease duration

Glial Fibrillary Acidic Protein (GFAP)

• Astrocytic marker

• Elevated in PSP

• Reflects astrocytic pathology

Iron Metabolism Markers

Ferritin

• Elevated in PSP CSF^{8'CSF ferritin in PSP: Iron dysregulation'2021}

• Reflects iron dysregulation

• Correlates with disease severity

• Related to brain iron accumulation

Hepcidin

• Altered iron metabolism

• Potential biomarker for PSP

Lipid and Membrane Markers

Apolipoprotein E (ApoE)

• ApoE4 associated with faster progression^{9Apolipoprotein E and progression in PSP2022}

• Influences tau pathology

• Lipid metabolism alterations in PSP

Sphingolipids

• Altered in PSP CSF

• Related to myelin degeneration

Blood-Based Biomarkers

Plasma and Serum Tau

Total Tau (t-tau)

• Elevated in PSP vs. healthy controls

• Similar pattern to CSF but lower sensitivity

• Potential for screening

Phosphorylated Tau (p-tau)

• p-tau181: Elevated in PSP, lower than AD^{10Plasma p-tau181 in PSP and other parkinsonian disorders2021 · PMID 33221845Open reference}

• p-tau217: Promising for 4R-tauopathies

• Can distinguish PSP from PD

• Emerging use in clinical trials

Tau Fragments

• Various tau fragments detectable in blood

• Disease-specific patterns emerging

Blood Neurofilament Light Chain (NfL)

• Reliably elevated in PSP plasma/serum^{2Neurofilament light chain in CSF and plasma as progression markers in PSP2022 · PMID 34897654Open reference}0

• Correlates with CSF NfL

• Excellent for disease monitoring

• Predicts progression

• Used as endpoint in clinical trials

Neuroinflammatory Markers in Blood

IL-6, TNF-α, YKL-40

• Elevated in PSP blood

• Less robust than CSF findings

• Research utility

Blood Iron Markers

• Serum ferritin elevated

• Reflects systemic iron dysregulation

Emerging Blood Biomarkers

Neuronal-Derived Exosomes (NDEs)

• Tau enrichment in neuronal exosomes^{2Neurofilament light chain in CSF and plasma as progression markers in PSP2022 · PMID 34897654Open reference}1

• Specific tau strains in exosomes

• Promising for differential diagnosis

Cell-Free DNA

• Increased levels in PSP

• Potential for early detection

Comparison with Other Biomarker Sources

CSF vs. Blood

Biomarker Panels

Multi-marker panels improve diagnostic accuracy:

• t-tau + NfL + IL-6: High discrimination

• p-tau217 + NfL: Progression prediction

• Tau oligomers + NfL: Disease staging

Clinical Applications

Diagnosis

Fluid biomarkers aid in differential diagnosis:

• PSP vs. PD: NfL, t-tau elevated in PSP

• PSP vs. CBS: Different p-tau patterns

• PSP vs. AD: Lower p-tau181, different p-tau217 patterns

Disease Monitoring

Serial measurements track progression:

• NfL: Annual change correlates with clinical decline

• t-tau: Progression marker

• p-tau: May plateau in later stages

Clinical Trials

Fluid biomarkers serve as:

• Enrollment criteria: Enrich for specific biomarker profiles

• Endpoint measures: NfL as progression marker

• Pharmacodynamic markers: Target engagement indicators

Prognostic Applications

• Baseline NfL predicts progression rate

• p-tau patterns predict phenotype

• Multiple markers improve prognostic accuracy

Methodological Considerations

Preanalytical Factors

• Collection: Standardized lumbar puncture protocol

• Storage: -80°C storage, avoid freeze-thaw cycles

• Timing: Morning collection preferred

Assay Methods

• ELISA: Most common, standardized

• Simoa: Ultra-sensitive for low-abundance proteins

• Mass spectrometry: For precise tau species measurement

• Multiplex: For biomarker panels

Reference Values

• Laboratory-specific cutoffs

• Age-adjusted reference ranges

• Disease-specific thresholds emerging

Integration with Neuroimaging

Fluid biomarkers complement imaging:

• NfL + MRI: Progression assessment

• p-tau + Tau PET: Pathology confirmation

• Multiple markers + DTI: Network degeneration

Future Directions

Technical Developments

• Ultra-sensitive assays improving detection

• Standardization across laboratories

• Point-of-care testing potential

Biomarker Discovery

• Tau strain-specific antibodies

• Single-molecule detection

• Multi-omic approaches

Clinical Implementation

• Validation in large cohorts

• FDA/EMA approval pathways

• Integration into diagnostic criteria

See Also

• PSP Neuroimaging

• PSP Disease Progression Staging

• Tau Aggregate Specificity

• Neuroimmune Biomarkers in PSP

• Progressive Supranuclear Palsy

• Cortical-Basal Degeneration